← Back to Clinical Trials
Recruiting NCT06141811
A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-302 Clinical Trial
Trial Parameters
Condition Diabetic Foot Ulcer
Sponsor Anterogen Co., Ltd.
Study Type OBSERVATIONAL
Phase N/A
Enrollment 104
Sex ALL
Min Age 19 Years
Max Age 75 Years
Start Date 2023-04-25
Completion 2025-12-31
Interventions
ALLO-ASC-DFUVehicle sheet
Brief Summary
This is a follow-up study to evaluate the safety for the subjects with ALLO-ASC-DFU treatment in phase 3 clinical trial (ALLO-ASC-DFU-302) for 24 months
Eligibility Criteria
Inclusion Criteria: 1. Subjects who are treated with ALLO-ASC-DFU sheet or Vehicle sheet in phase 3 clinical trial of ALLO-ASC-DFU-302. 2. Subjects who are able to give written informed consent prior to study start and to comply with the study requirements. Exclusion Criteria: 1\. Subjects who are considered not suitable for the study by the principal investigator.
Related Trials
NCT07291817
Intermittent Negative Pressure for Patients With Diabetic Foot Ulcers (INPRESS) Study
View Trial →
NCT06531512
Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabeti
View Trial →
NCT06141811
A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-302 Clinical Trial
View Trial →